Hikma Publishes Transcript of R&D Spotlight on Respiratory, Nasal, Semi-Solids and Liquids
Bitget2026/10/21 11:53- Hikma’s October 20, 2026, respiratory, nasal, semi-solids and liquids R&D spotlight featured global R&D head Hafrun Fridriksdottir and platform head Chris Edlin.
- Intranasal epinephrine is under US regulatory review, with FDA feedback expected in the first half of 2027.
- Respimat submission timing has slipped following technical challenges, but management does not expect a material impact on launches targeted around patent expiry.
- The Ellipta program has generated human data supporting device selection; commercial manufacturing capability is being established in Columbus.
- Higher R&D investment targets opportunities across three platforms, including a greater focus on first-to-file and first-to-market solid oral products.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Brent: Election-driven risk premium unwinds – ING
Mirae Asset Cuts Hanwha REIT Stake to 26.41% From 26.44%
Diageo (DEO.US) Q1 organic sales unexpectedly rose 1.4%: North America declined 3.6%, becoming a drag, while the full-year flat guidance remains unchanged.
Diageo's first-quarter organic net sales unexpectedly rose by 1.4% to $4.93 billion, with Latin America and Asia Pacific leading the growth, while North America still declined by 3.6%. The company maintains its guidance of flat performance for the full year.
Deutsche Bank raises EchoStar Communications target price to $134
Crypto prices
More
